Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Heron Therapeutics Inc (HRTX) vs Liberty Global Ltd Class C (LBTYK) Price & Performance

Heron Therapeutics IncTrade
Liberty Global Ltd Class CTrade

Price performance (Past 24H)

Key statistics

Heron Therapeutics Inc vs Liberty Global Ltd Class C — how do they compare? Heron Therapeutics Inc trades at $0.33 (market cap $61.47M), while Liberty Global Ltd Class C trades at $10.11 (market cap $3.48B). The key difference: Liberty Global Ltd Class C is far larger — about 56.6× Heron Therapeutics Inc's market cap, and Liberty Global Ltd Class C is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.

HRTXLBTYK
Market Cap
$61.47M$3.48B
Sector
HealthTechnology
52-Week High
$1.49$12.67
52-Week Low
$0.32$9.59
Enterprise Value
$168.21M$10.13B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Heron Therapeutics Inc

HRTX trades at $0.3152, down 4.54% today, amid bearish technical signals and mixed earnings. The stock shows a high gross margin of 70.07% but negative net income margins, with Q2 2026 missing revenue and EPS estimates. Recent news highlights patent litigation developments and quarterly results falling short of expectations, contributing to investor caution.

The outlook remains challenged by persistent losses and operational cash burn, though analyst consensus is strongly bullish with 94.74% buy ratings. Key risks include execution on product sales, competitive pressures, and reliance on financing activities to sustain operations amid negative profitability.

Liberty Global Ltd Class C

LBTYK trades at $10.015, up 0.25% on the day, amid a bearish technical signal but strong analyst support. The stock shows mixed earnings, with a Q1 2026 beat but Q4 2025 and Q2 2026 misses, while the company navigates the Ziggo Group spin-off planned for 2027. Financially, it has a low P/S of 0.7 and P/B of 0.37, but negative net income and ROE highlight profitability challenges, offset by solid operating cash flow of $1.21 billion in 2025.

The outlook is cautiously optimistic, with the Ziggo Group listing in 2027 offering a potential catalyst, but persistent losses and competitive pressures pose risks. Analyst consensus is strongly bullish with 69% buy ratings, suggesting underlying value despite near-term headwinds.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX

About Liberty Global Ltd Class C

Liberty Global is a world leader in converged broadband, video, and mobile communications. It operates large-scale fiber and 5G networks across Europe, providing essential digital services to millions of customers.

Read more on LBTYK